Literature DB >> 7643548

In vitro formation of advanced glycation end products in peritoneal dialysis fluid.

E J Lamb1, W R Cattell, A B Dawnay.   

Abstract

Glycation of proteins in the peritoneum might occur due to the extremely high glucose concentrations (75 to 214 mmol/liter) in the dialysate of patients on continuous ambulatory peritoneal dialysis (CAPD) and may be involved in the etiology of ultrafiltration failure. Formation of both early (glycated albumin) and late (advanced glycation end products; AGE, measured as protein-derived fluorescence intensity, FI) Maillard reaction products was studied in vitro in dialysis fluids obtained from seven patients on CAPD and in phosphate buffered saline (PBS) controls paired for glucose and albumin concentrations. Percentage glycated albumin (median, range) increased (P < 0.02) from baseline after 10 and 21 days in both dialysate and PBS but did not differ (P > 0.05) between the two media at any time point (day 0, 3.6, 3.1-4.5 vs. 4.1, 3.0-4.6; day 10, 19.4, 7.9-54.8 vs. 19.1, 8.7-50.1; day 21, 29.0, 12.0-75.6 vs. 30.0, 11.7-69.8). Glycated albumin formation was linearly related to the glucose concentration (r > 0.98, P < 0.001) in both dialysate and PBS at 10 and 21 days. FI (U/g/liter albumin, median, range) increased (P < 0.02) from baseline after 10 and 21 days in dialysate but only after 21 days in PBS; this increase was significantly greater (P < 0.02) in dialysate than in PBS after 10 and 21 days (day 0, 41, 36-46 vs. 42, 37-46; day 10, 99, 88-161 vs. 51, 34-68; day 21, 113, 102-239 vs. 68, 54-91). After 21 days, FI was significantly related to glucose concentration (r = 0.90, P < 0.01) and to % glycated albumin (r = 0.92, P < 0.01) in PBS but not in dialysate (P > 0.05). AGE formation, but not glycation, decreased as a function of the dialysate dwell time and was inhibited by aminoguanidine. Our results demonstrate that formation of AGE products occurs in dialysis fluid and that factors in dialysate can modulate this process.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7643548     DOI: 10.1038/ki.1995.244

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  6 in total

1.  Intercellular localization of occludins and ZO-1 as a solute transport barrier of the mesothelial monolayer.

Authors:  Ken-ichi Kaneda; Keiichi Miyamoto; Shinsuke Nomura; Takashi Horiuchi
Journal:  J Artif Organs       Date:  2006-12-21       Impact factor: 1.731

Review 2.  Pharmacologic targets and peritoneal membrane remodeling.

Authors:  Karima Farhat; Andrea W D Stavenuiter; Rob H J Beelen; Piet M Ter Wee
Journal:  Perit Dial Int       Date:  2014 Jan-Feb       Impact factor: 1.756

Review 3.  Role of advanced glycation endproducts and potential therapeutic interventions in dialysis patients.

Authors:  Sandeep K Mallipattu; John C He; Jaime Uribarri
Journal:  Semin Dial       Date:  2012-04-30       Impact factor: 3.455

Review 4.  Peritoneal adipocytes and their role in inflammation during peritoneal dialysis.

Authors:  Kar Neng Lai; Joseph C K Leung
Journal:  Mediators Inflamm       Date:  2010-05-05       Impact factor: 4.711

5.  Differential expression of receptors for advanced glycation end-products in peritoneal mesothelial cells exposed to glucose degradation products.

Authors:  K N Lai; J C K Leung; L Y Y Chan; F F K Li; S C W Tang; M F Lam; K C Tse; T P Yip; T M Chan; A Wieslander; H Vlassara
Journal:  Clin Exp Immunol       Date:  2004-12       Impact factor: 4.330

6.  Biocompatible dialysis fluids for peritoneal dialysis.

Authors:  Htay Htay; David W Johnson; Kathryn J Wiggins; Sunil V Badve; Jonathan C Craig; Giovanni Fm Strippoli; Yeoungjee Cho
Journal:  Cochrane Database Syst Rev       Date:  2018-10-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.